The combination of PTC596 and S63845 may be an effective treatment in CD34 positive AML with elevated MCL1 protein levels, while PTC596 and trametinib may be more effective in CD34 positive AML with elevated MEK1 protein levels, including TP53 mutant AML. Here, MCL1 is linked to acute myeloid leukemia.